Innate Pharma S.A. (IPHA) Financials

$2.15

$0.04 (1.66%)
Last update: 10:19 AM EST
Day's range
$2.11
Day's range
$2.17

IPHA Income statement / Annual

Last year (2024), Innate Pharma S.A.'s total revenue was $12.62 M, a decrease of 75.68% from the previous year. In 2024, Innate Pharma S.A.'s net income was -$49.47 M. See Innate Pharma S.A.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Operating Revenue $12.62 M $51.90 M $57.67 M $12.11 M $69.77 M $68.97 M $79.89 M $32.63 M $56.16 M $17.91 M
Cost of Revenue $0.00 $56.02 M $51.66 M $47.00 M $49.71 M $45.16 M $69.56 M $67.00 M $48.63 M $29.91 M
Gross Profit $12.62 M -$4.12 M -$2.02 M -$34.89 M $20.07 M $23.82 M $10.34 M -$34.37 M $7.53 M -$12.00 M
Gross Profit Ratio 1 -0.08 -0.04 -2.88 0.29 0.35 0.13 -1.05 0.13 -0.67
Research and Development Expenses $51.98 M $56.02 M $51.66 M $47.00 M $49.71 M $1.60 M $69.56 M $67.00 M $48.63 M $29.91 M
General & Administrative Expenses $11.93 M $11.75 M $14.47 M $15.99 M $18.58 M $40.73 M $18.14 M $15.66 M $8.88 M $5.59 M
Selling & Marketing Expenses $0.00 $0.00 $7.96 M $9.53 M $408,000.00 $8.85 M $1.11 M $527,000.00 $450,000.00 $288,000.00
Selling, General & Administrative Expenses $11.93 M $11.75 M $14.47 M $25.52 M $18.99 M $49.58 M $19.25 M $16.18 M $9.33 M $5.88 M
Other Expenses $283,000.00 -$3.20 M -$8.04 M -$12.59 M -$49.71 M -$309,000.00 -$14.06 M -$10.57 M -$9.37 M -$7.11 M
Operating Expenses $64.20 M $64.57 M $66.06 M $59.94 M $18.99 M $50.87 M $74.75 M $72.61 M $48.59 M $28.68 M
Cost And Expenses $64.20 M $64.57 M $107.01 M $59.94 M $68.69 M $96.03 M $74.75 M $72.61 M $48.59 M $28.68 M
Interest Income $2.44 M $3.18 M $4.78 M $6.34 M $564,000.00 $1.62 M $1.58 M $1.25 M $0.00 $27,000.00
Interest Expense $566,000.00 $640,000.00 $288,000.00 $4.00 M $341,000.00 $204,000.00 $102,000.00 $113,000.00 $124,000.00 $139,000.00
Depreciation & Amortization $1.99 M $5.09 M $45.41 M $4.57 M $12.23 M $16.53 M $7.40 M $4.40 M $3.26 M $2.66 M
EBITDA -$46.91 M -$1.84 M -$12.28 M -$43.23 M $13.31 M -$20.86 M -$3.30 M -$35.65 M $10.83 M -$8.09 M
EBITDA Ratio -3.72 -0.04 -0.21 -3.57 0.19 -0.3 -0.04 -1.09 0.19 -0.45
Operating Income Ratio -4.09 -0.24 -1 -3.95 0.02 -0.39 0.06 -1.23 0.13 -0.6
Total Other Income/Expenses Net $2.10 M $5.10 M -$547,000.00 $2.35 M -$1.91 M $6.29 M -$2.43 M -$8.03 M $5.37 M $4.07 M
Income Before Tax -$49.47 M -$7.57 M -$57.97 M -$45.48 M -$829,000.00 -$20.76 M $2.72 M -$48.02 M $12.94 M -$6.71 M
Income Before Tax Ratio -3.92 -0.15 -1.01 -3.75 -0.01 -0.3 0.03 -1.47 0.23 -0.37
Income Tax Expense $0.00 $0.00 $41.13 M $13.66 M $0.00 $206,000.00 -$333,000.00 $368,000.00 $301,000.00 $139,000.00
Net Income -$49.47 M -$7.57 M -$58.10 M -$59.14 M -$63.98 M -$20.97 M $3.05 M -$48.39 M $12.64 M -$6.71 M
Net Income Ratio -3.92 -0.15 -1.01 -4.88 -0.92 -0.3 0.04 -1.48 0.23 -0.37
EPS -0.61 -0.09 -0.73 -0.74 -0.0105 -0.31 0.0519 -0.89 0.23 -0.13
EPS Diluted -0.61 -0.09 -0.73 -0.74 -0.0105 -0.31 0.0519 -0.89 0.23 -0.13
Weighted Average Shares Out $81.05 M $84.11 M $79.59 M $79.54 M $78.93 M $66.91 M $58.78 M $54.35 M $53.87 M $51.58 M
Weighted Average Shares Out Diluted $81.05 M $84.11 M $79.64 M $79.54 M $78.93 M $66.91 M $58.78 M $54.35 M $53.87 M $53.40 M
Link